Coherus Oncology (CHRS) Earnings Date & Reports

Key Takeaways

• Coherus Oncology (CHRS) is scheduled to report its third quarter 2026 results after the market close on Monday, November 9, 2026.
• Analysts expect a net loss of roughly $0.22 per share, a narrower loss than the $0.31 per share reported in the same quarter a year earlier.
• Consensus revenue estimates sit near $15.9 million, implying an increase of approximately 37% year over year, driven primarily by its flagship drug LOQTORZI.
• Investors are watching LOQTORZI's commercial ramp, clinical pipeline readouts, and the company's cash runway heading into the report.
• CHRS has historically delivered sharp, often outsized stock moves around earnings, making this an event-heavy date for shareholders.
• For additional context on this ticker, you can explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To uncover AI-driven trading ideas across the broader market, you can also explore Trending AI Robots.

Earnings Context and Why It Matters

Coherus Oncology is a commercial-stage immuno-oncology company that has undergone a major transformation, divesting its biosimilar businesses to focus exclusively on innovative cancer medicines. Its commercial centerpiece is LOQTORZI (toripalimab), a next-generation PD-1 inhibitor (a therapy that helps the immune system attack tumors). This report matters because it will show whether LOQTORZI's recent sales momentum is durable and whether the company can narrow its losses as it scales. With a limited cash position and a clinical pipeline requiring significant investment, investors are closely tracking both revenue growth and expense discipline to gauge how long the current runway can support key upcoming data readouts.

Earnings Expectations

Wall Street consensus for the third quarter of 2026 calls for a net loss of approximately $0.22 per share, according to analyst estimates, which would represent a meaningful improvement from the $0.31 per share loss recorded in the third quarter of 2025. Revenue is expected to reach roughly $15.9 million, up about 37% from the $11.6 million reported in the prior-year period.

The top-line expectation is anchored by LOQTORZI, where management has guided toward reaching approximately $15 million per quarter during 2026 and 10% to 15% average demand growth per quarter for the year. In the first quarter of 2026, the company posted LOQTORZI net sales of $11.8 million, up 61% year over year. For the full year, analysts model revenue of roughly $60 million and a loss of about $0.88 per share.

Beyond the headline figures, investors will focus on net sales growth, new patient starts, operating expense trends (including research and development and selling, general, and administrative costs), and any updated commentary on the company's cash position. Historically, CHRS has beaten earnings-per-share estimates in only a minority of recent quarters, while revenue performance has been mixed, contributing to volatile post-earnings price reactions.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. If you are researching companies like CHRS or scanning for emerging patterns across the healthcare sector, the AI Screener offers a streamlined way to surface actionable candidates.

Market Reaction and Investor Sentiment

Sentiment heading into the third quarter report remains cautious but watchful. CHRS shares have traded well below their 52-week highs, and the stock carries elevated short interest, indicating meaningful skepticism among some market participants. At the same time, the analyst consensus rating is broadly positive, with an average price target well above the current share price, reflecting a split between near-term bearishness and longer-term optimism tied to the pipeline.

The company's shares have a track record of pronounced moves around earnings, with both large single-day gains and double-digit declines following recent reports. Key risk factors heading into the release include any softness in LOQTORZI demand, slower-than-expected new patient starts, higher-than-anticipated operating expenses, or any signal that the company may need to raise additional capital. Conversely, a strong revenue beat or clearer visibility into clinical catalysts could drive a sharp positive reaction.

Forward Outlook and Key Factors to Monitor

Looking beyond the third quarter print, investors should track several factors that will shape Coherus Oncology's trajectory. The most important is LOQTORZI's continued commercial execution. Management has outlined a ramp toward roughly $15 million in quarterly sales during 2026, expanding to $30 million to $35 million per quarter in 2027. Whether the company stays on that path will be a central focus.

The clinical pipeline represents another key driver. Coherus is advancing casdozokitug, an anti-IL-27 antibody, and tagmokitug across multiple cancer indications, with several early data readouts expected during 2026. Encouraging efficacy signals could validate the company's pivot to proprietary immuno-oncology assets, while disappointing data would raise questions about the broader pipeline strategy.

Finally, the balance sheet remains an area of close attention. With a meaningful cash burn and a limited runway, investors will monitor whether expense reductions and growing product revenue are sufficient to fund operations through the next wave of clinical milestones, or whether additional financing could dilute existing shareholders. These dynamics will likely keep volatility elevated in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations